Proteasomal degradation of TRIM5α during retrovirus restriction

PLoS Pathogens

Volumn 4, Issue 5, 2008, Pages

  Rold, Christopher James ^a   Aiken, Christopher ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; CYCLOSPORIN A; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN TRIMCYP; TRIPARTITE MOTIF PROTEIN 5; CARRIER PROTEIN; CORE PROTEIN; CYCLOSPORIN; ENZYME INHIBITOR; PROTEIN; SMALL INTERFERING RNA; TRIM5 PROTEIN, HUMAN; TRIM5(ALPHA) PROTEIN, RHESUS MONKEY;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MURINE LEUKEMIA VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN DEGRADATION; RETROVIRUS INFECTION; REVERSE TRANSCRIPTION; RHESUS MONKEY; VIRUS CAPSID; VIRUS CORE; VIRUS ENTRY; VIRUS PARTICLE; ANIMAL; AOTUS; CELL LINE; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; HOST PATHOGEN INTERACTION; MACACA; METABOLISM; PHYSIOLOGY; RETROVIRUS;

AOTUS TRIVIRGATUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; MIRIDAE; MURINE LEUKEMIA VIRUS;

ANIMALS; AOTIDAE; CARRIER PROTEINS; CELL LINE; CYCLOSPORINE; ENZYME INHIBITORS; GENE SILENCING; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MACACA MULATTA; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEINS; RETROVIRIDAE; REVERSE TRANSCRIPTION; RNA, SMALL INTERFERING; TRANSFECTION; VIRAL CORE PROTEINS;

EID: 44949201552     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000074     Document Type: Article

References (81)

1. Best S, Le Tissier P, Towers G, Stoye JP (1996) Positional cloning of the mouse retrovirus restriction gene Fv1. Nature 382: 826-829.
2. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
3. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, et al. (2004) The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427: 848-853.
4. Sayah DM, Sokolskaja E, Berthoux L, Luban J (2004) Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430: 569-573.
5. Nisole S, Lynch C, Stoye JP, Yap MW (2004) A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc Natl Acad Sci U S A 101: 13324-13328.
6. Bieniasz PD (2004) Intrinsic immunity: a front-line defense against viral attack. Nat Immunol 5: 1109-1115.
7. Goff SP (2004) Retrovirus restriction factors. Mol Cell 16: 849-859.
8. Harris RS, Liddament MT (2004) Retroviral restriction by APOBEC proteins. Nat Rev Immunol 4: 868-877.
9. Holmes RK, Malim MH, Bishop KN (2007) APOBEC-mediated viral restriction: not simply editing? Trends Biochem Sci 32: 118-128.
10. Sokolskaja E, Luban J (2006) Cyclophilin, TRIM5, and innate immunity to HIV-1. Curr Opin Microbiol 9: 404-408.
11. Pincus T, Hartley JW, Rowe WP (1975) A major genetic locus affecting resistance to infection with murine leukemia viruses. IV. Dose-response relationships in Fv-1-sensitive and resistant cell cultures. Virology 65: 333-342.
12. Pincus T, Hartley JW, Rowe WP (1971) A major genetic locus affecting resistance to infection with murine leukemia viruses. I. Tissue culture studies of naturally occurring viruses. J Exp Med 133: 1219-1233.
13. Lilly F (1967) Susceptibility to two strains of Friend leukemia virus in mice. Science 155: 461-462.
14. Pryciak PM, Varmus HE (1992) Fv-1 restriction and its effects on murine leukemia virus integration in vivo and in vitro. J Virol 66: 5959-5966.
15. Jolicoeur P, Rassart E (1980) Effect of Fv-1 gene product on synthesis of linear and supercoiled viral DNA in cells infected with murine leukemia virus. J Virol 33: 183-195.
16. Boone LR, Innes CL, Heitman CK (1990) Abrogation of Fv-1 restriction by genome-deficient virions produced by a retrovirus packaging cell line. J Virol 64:3376-3381.
17. Kozak CA, Chakraborti A (1996) Single Amino Acid Changes in the Murine Leukemia Virus Capsid Protein Gene Define the Target of Fv1Resistance. Virology 225: 300.
18. DesGroseillers L, Jolicoeur P (1983) Physical mapping of the Fv-1 tropism host range determinant of BALB/c murine leukemia viruses. J Virol 48: 685-696.
19. Boone LR, Myer FE, Yang DM, Ou CY, Koh CK, et al. (1983) Reversal of Fv-1 host range by in vitro restriction endonuclease fragment exchange between molecular clones of N-tropic and B-tropic murine leukemia virus genomes. J Virol 48: 110-119.
20. Munk C, Brandt SM, Lucero G, Landau NR (2002) A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc Natl Acad Sci U S A 99: 13843-13848.
21. Hofmann W, Schubert D, LaBonte J, Munson L, Gibson S, et al. (1999) Species-specific, postentry barriers to primate immunodeficiency virus infection. J Virol 73: 10020-10028.
22. Hatziioannou T, Cowan S, Goff SP, Bieniasz PD, Towers GJ (2003) Restriction of multiple divergent retroviruses by Lv1 and Ref1. Embo J 22: 385-394.
23. Cowan S, Hatziioannou T, Cunningham T, Muesing MA, Gottlinger HG, et al. (2002) Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc Natl Acad Sci U S A 99: 11914-11919.
24. Besnier C, Takeuchi Y, Towers G (2002) Restriction of lentivirus in monkeys. Proc Natl Acad Sci U S A 99: 11920-11925.
25. Schmitz C, Marchant D, Neil SJ, Aubin K, Reuter S, et al. (2004) Lv2, a novel postentry restriction, is mediated by both capsid and envelope. J Virol 78: 2006-2016.
26. Owens CM, Yang PC, Gottlinger H, Sodroski J (2003) Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells. J Virol 77: 726-731.
27. Kootstra NA, Munk C, Tonnu N, Landau NR, Verma IM (2003) Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. Proc Natl Acad Sci U S A 100: 1298-1303.
28. Ylinen LM, Keckesova Z, Wilson SJ, Ranasinghe S, Towers GJ (2005) Differential restriction of human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac by TRIM5alpha alleles. J Virol 79: 11580-11587.
29. Hatziioannou T, Perez-Caballero D, Yang A, Cowan S, Bieniasz PD (2004) Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci U S A 101: 10774-10779.
30. Keckesova Z, Ylinen LM, Towers GJ (2004) The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc Natl Acad Sci U S A 101: 10780-10785.
31. Song B, Javanbakht H, Perron M, Park DH, Stremlau M, et al. (2005) Retrovirus Restriction by TRIM5{alpha} Variants from Old World and New World Primates. J Virol 79: 3930-3937.
32. Yap MW, Nisole S, Stoye JP (2005) A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol 15: 73-78.
33. Yap MW, Nisole S, Lynch C, Stoye JP (2004) Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci U S A 101: 10786-10791.
34. Stremlau M, Perron M, Welikala S, Sodroski J (2005) Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J Virol 79: 3139-3145.
35. Saenz DT, Teo W, Olsen JC, Poeschla EM (2005) Restriction of feline immunodeficiency virus by Ref1, Lv1, and primate TRIM5alpha proteins. J Virol 79: 15175-15188.
36. Perron MJ, Stremlau M, Song B, Ulm W, Mulligan RC, et al. (2004) TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc Natl Acad Sci U S A 101: 11827-11832.
37. Zhang F, Hatziioannou T, Perez-Caballero D, Derse D, Bieniasz PD (2006) Antiretroviral potential of human tripartite motif-5 and related proteins. Virology 353: 396-409.
38. Towers GJ, Hatziioannou T, Cowan S, Goff SP, Luban J, et al. (2003) Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med 9: 1138-1143.
39. Brennan G, Kozyrev Y, Hu SL (2008) TRIMCyp expression in Old World primates Macaca nemestrina and Macaca fascicularis. Proc Natl Acad Sci U S A 105: 3569-3574.
40. Liao CH, Kuang YQ, Liu HL, Zheng YT, Su B (2007) A novel fusion gene, TRIM5-Cyclophilin A in the pig-tailed macaque determines its susceptibility to HIV-1 infection. Aids 21 Suppl 8: S19-26.
41. Virgen CA, Kratovac Z, Bieniasz PD, Hatziioannou T (2008) Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. Proc Natl Acad Sci U S A 105: 3563-3568.
42. Wilson SJ, Webb BL, Ylinen LM, Verschoor E, Heeney JL, et al. (2008) Independent evolution of an antiviral TRIMCyp in rhesus macaques. Proc Natl Acad Sci U S A 105: 3557-3562.
43. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, et al. (2001) The tripartite motif family identifies cell compartments. Embo J 20: 2140-2151.
44. Perez-Caballero D, Hatziioannou T, Yang A, Cowan S, Bieniasz PD (2005) Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J Virol 79: 8969-8978.
45. Ohkura S, Yap MW, Sheldon T, Stoye JP (2006) All three variable regions of the TRIM5alpha B30.2 domain can contribute to the specificity of retrovirus restriction. J Virol 80: 8554-8565.
46. Nakayama EE, Miyoshi H, Nagai Y, Shioda T (2005) A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5alpha determines species-specific restriction of simian immunodeficiency virus SIVmac infection. J Virol 79: 8870-8877.
47. Mische CC, Javanbakht H, Song B, Diaz-Griffero F, Stremlau M, et al. (2005) Retroviral restriction factor TRIM5alpha is a trimer. J Virol 79: 14446-14450.
48. Javanbakht H, Yuan W, Yeung DF, Song B, Diaz-Griffero F, et al. (2006) Characterization of TRIM5alpha trimerization and its contribution to human immunodeficiency virus capsid binding. Virology 353: 234-246.
49. Javanbakht H, Diaz-Griffero F, Stremlau M, Si Z, Sodroski J (2005) The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5alpha. J Biol Chem 280: 26933-26940.
50. Yap MW, Dodding MP, Stoye JP (2006) Trim-cyclophilin A fusion proteins can restrict human immunodeficiency virus type 1 infection at two distinct phases in the viral life cycle. J Virol 80: 4061-4067.
51. Li X, Li Y, Stremlau M, Yuan W, Song B, et al. (2006) Functional replacement of the RING, B-box 2, and coiled-coil domains of tripartite motif 5alpha (TRIM5alpha) by heterologous TRIM domains. J Virol 80: 6198-6206.
52. Li X, Gold B, O'HUigin C, Diaz-Griffero F, Song B, et al. (2007) Unique features of TRIM5alpha among closely related human TRIM family members. Virology 360: 419-433.
53. Meroni G, Diez-Roux G (2005) TRIM/RBCC, a novel class of 'single protein RING finger' E3 ubiquitin ligases. Bioessays 27: 1147-1157.
54. Jackson PK, Eldridge AG, Freed E, Furstenthal L, Hsu JY, et al. (2000) The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol 10: 429-439.
55. Diaz-Griffero F, Li X, Javanbakht H, Song B, Welikala S, et al. (2006) Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5. Virology 349: 300-315.
56. Xu L, Yang L, Moitra PK, Hashimoto K, Rallabhandi P, et al. (2003) BTBD1 and BTBD2 colocalize to cytoplasmic bodies with the RBCC/tripartite motif protein, TRIM5delta. Exp Cell Res 288: 84-93.
57. Perez-Caballero D, Hatziioannou T, Zhang F, Cowan S, Bieniasz PD (2005) Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. J Virol 79: 15567-15572.
58. Wu X, Anderson JL, Campbell EM, Joseph AM, Hope TJ (2006) Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc Natl Acad Sci U S A 103: 7465-7470.
59. Anderson JL, Campbell EM, Wu X, Vandegraaff N, Engelman A, et al. (2006) Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins. J Virol 80: 9754-9760.
60. Shi J, Aiken C (2006) Saturation of TRIM5[alpha]-mediated restriction of HIV-1 infection depends on the stability of the incoming viral capsid. Virology 350: 493.
61. Forshey BM, Shi J, Aiken C (2005) Structural Requirements for Recognition of the Human Immunodeficiency Virus Type 1 Core during Host Restriction in Owl Monkey Cells. J Virol 79: 869-875.
62. Campbell EM, Dodding MP, Yap MW, Wu X, Gallois-Montbrun S, et al. (2007) TRIM5{alpha} Cytoplasmic Bodies Are Highly Dynamic Structures. Mol Biol Cell 18: 2102-2111.
63. Diaz-Griffero F, Kar A, Perron M, Xiang SH, Javanbakht H, et al. (2007) Modulation of retroviral restriction and proteasome inhibitor-resistant turnover by changes in the TRIM5alpha B-box 2 domain. J Virol 81: 10362-10378.
64. Forshey BM, von Schwedler U, Sundquist WI, Aiken C (2002) Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J Virol 76: 5667-5677.
65. Stremlau M, Perron M, Lee M, Li Y, Song B, et al. (2006) Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci U S A 103: 5514-5519.
66. Perron MJ, Stremlau M, Lee M, Javanbakht H, Song B, et al. (2007) The human TRIM5alpha restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid. J Virol 81: 2138-2148.
67. Diaz-Griffero F, Kar A, Lee M, Stremlau M, Poeschla E, et al. (2007) Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp. Virology 369: 400-410.
68. Chatterji U, Bobardt MD, Gaskill P, Sheeter D, Fox H, et al. (2006) Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry. J Biol Chem 281: 37025-37033.
69. Galla M, Schambach A, Towers GJ, Baum C (2008) Cellular restriction of retrovirus particle-mediated mRNA transfer. J Virol 82: 3069-3077.
70. Campbell EM, Perez O, Anderson JL, Hope TJ (2008) Visualization of a proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5alpha. J Cell Biol 180: 549-61.
71. Hoyt MA, Coffino P (2004) Ubiquitin-free routes into the proteasome. Cell Mol Life Sci 61: 1596-1600.
72. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM (2000) Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53. J Biol Chem 275: 8945-8951.
73. Ohta T, Michel JJ, Xiong Y (1999) Association with cullin partners protects ROC proteins from proteasome-dependent degradation. Oncogene 18: 6758-6766.
74. Lu Y, Amleh A, Sun J, Jin X, McCullough SD, et al. (2007) Ubiquitination and proteasome-mediated degradation of BRCA1 and BARD1 during steroidogenesis in human ovarian granulosa cells. Mol Endocrinol 21: 651-663.
75. Boutell C, Canning M, Orr A, Everett RD (2005) Reciprocal activities between herpes simplex virus type 1 regulatory protein ICP0, a ubiquitin E3 ligase, and ubiquitin-specific protease USP7. J Virol 79: 12342-12354.
76. Bock M, Bishop KN, Towers G, Stoye JP (2000) Use of a transient assay for studying the genetic determinants of Fv1 restriction. J Virol 74: 7422-7430.
77. Aiken C (1997) Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol 71: 5871-5877.
78. He J, Chen Y, Farzan M, Choe H, Ohagen A, et al. (1997) CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 385: 645-649.
79. Naviaux RK, Costanzi E, Haas M, Verma IM (1996) The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J Virol 70: 5701-5705.
80. Yee JK, Friedmann T, Burns JC (1994) Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol 43 Pt A: 99-112.
81. Morgenstern JP, Land H (1990) Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 18: 3587-3596.